Modality
Cell Therapy
MOA
SHP2i
Target
CD19
Pathway
Hedgehog
MSPSP
Development Pipeline
Preclinical
Feb 2024
→ Feb 2026
PreclinicalCurrent
NCT05460381
2,974 pts·PSP
2024-02→2026-02·Terminated
2,974 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-02-261mo agoInterim· PSP
Trial Timeline
Q2Q3Q42025Q2Q3Q42026
Preclinical
Termina…
Catalysts
Interim
2026-02-26 · 1mo ago
PSP
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05460381 | Preclinical | PSP | Terminated | 2974 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Doxacagene | Sanofi | Approved | PSMA | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| Daratuximab | BioMarin | Phase 1 | PRMT5 | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | TROP-2 | |
| 369-4107 | Hansoh Pharma | Phase 2 | TNFα |